Opinion

Video

Emerging Molecular Biomarkers in Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOG

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.

Video content above is prompted by the following:

Emerging Molecular Biomarkers Beyond BRCA/HRD

Several important biomarkers guide ovarian cancer treatment beyond BRCA and HRD:

Tumor-agnostic biomarkers:

  • MSI/mismatch repair deficiency and TMB: Predict response to immunotherapy
  • HER2 (immunohistochemistry): Approved April 2024 for trastuzumab deruxtecan (FDA approved for 3+ expression; National Comprehensive Cancer Network recommends for 2+ also)

Diagnostic and predictive biomarkers:

  • p53: Distinguishes high-grade from low-grade serous ovarian cancer
  • KRAS: Expected to become an integrated biomarker for upcoming MEK/FAK inhibitor combination therapy in low-grade serous ovarian cancer
  • CCNE1 amplification: Mutually exclusive with BRCA mutations, associated with platinum resistance, with targeted therapies in development

The field continues to advance through collaborative research networks, including GOG Foundation and ENGOT, developing biomarker-directed treatments for gynecologic cancers.

Related Videos
5 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
1 expert in this video
Dr Gerard Criner
Dr Margrit Wiesendanger
4 experts are featured in this series.
Related Content
Women in science | Image Credit: © metamorworks-stock.adobe.com.jpeg
May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw
Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
May 22nd 2025

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

Brooke McCormick
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Patient consult | Image credit: Adobe Stock
May 18th 2025

Advances in Ovarian Cancer: Using Genomics and Optimizing Maintenance Therapy

Amy VanGalder, PharmD, BCOP
AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo